Aktienanalyse zu Nexgel Inc (NXGL)NXGLNexgel Inc

NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises is comprised of the CGN JV used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George. It also holds a portfolio of regenerative biomaterials which include Biovance, Biovance 3L, Natalin, and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Nexgel Inc is not a good buy right now due to significant financial instability and negative trends. The current price is $3.72, and the company has a troubling year-to-date change of -89.72%, indicating severe underperformance. Additionally, the RSI is at 37.396, suggesting the stock is nearing oversold territory, but this does not guarantee a rebound. The main risk is the upcoming earnings report on November 10, 2026, where the EPS estimate is -4.80, which could further pressure the stock if results disappoint.